We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Allogene Therapeutics (ALLO) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Allogene Therapeutics (ALLO - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Allogene Therapeutics is a member of our Medical group, which includes 889 different companies and currently sits at #1 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. ALLO is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ALLO's full-year earnings has moved 12.83% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, ALLO has moved about 93.23% on a year-to-date basis. In comparison, Medical companies have returned an average of -1.90%. This means that Allogene Therapeutics is performing better than its sector in terms of year-to-date returns.
To break things down more, ALLO belongs to the Medical - Biomedical and Genetics industry, a group that includes 382 individual companies and currently sits at #18 in the Zacks Industry Rank. This group has gained an average of 7.59% so far this year, so ALLO is performing better in this area.
Going forward, investors interested in Medical stocks should continue to pay close attention to ALLO as it looks to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Allogene Therapeutics (ALLO) Outperforming Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of Allogene Therapeutics (ALLO - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Allogene Therapeutics is a member of our Medical group, which includes 889 different companies and currently sits at #1 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. ALLO is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ALLO's full-year earnings has moved 12.83% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, ALLO has moved about 93.23% on a year-to-date basis. In comparison, Medical companies have returned an average of -1.90%. This means that Allogene Therapeutics is performing better than its sector in terms of year-to-date returns.
To break things down more, ALLO belongs to the Medical - Biomedical and Genetics industry, a group that includes 382 individual companies and currently sits at #18 in the Zacks Industry Rank. This group has gained an average of 7.59% so far this year, so ALLO is performing better in this area.
Going forward, investors interested in Medical stocks should continue to pay close attention to ALLO as it looks to continue its solid performance.